|Dr. Stefan Oschmann||Chairman of Exec. Board & CEO||8.3M||N/A||1957|
|Dr. Marcus Kuhnert||CFO & Member of Exec. Board||3.67M||N/A||1968|
|Dr. Kai Beckmann||CEO of Performance Materials & Member of the Exec. Board||3.92M||N/A||1965|
|Dr. Udit Batra||CEO of Life Science & Member of Exec. Board||4.3M||N/A||1971|
|Ms. Belén Garijo López M.D.||CEO of Healthcare & Member of the Exec. Board||4.54M||N/A||1960|
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; and collaboration with F-star Delta Ltd. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
MERCK Kommanditgesellschaft auf Aktien’s ISS governance QualityScore as of 5 December 2019 is 9. The pillar scores are Audit: 5; Board: 7; Shareholder rights: 8; Compensation: 8.